TGA Finds Semaglutide and No Retatrutide in a Vial Sold as Retatrutide (September 14, 2026)
TGA retatrutide alert, Sep 14, 2026: a vial sold as retatrutide held none, just semaglutide at about 8 times the approved level. What happened, what to do.
Event date Last verified Primary source Therapeutic Goods Administration (Australia)
The TGA retatrutide alert of September 14, 2026 is about a vial that held no retatrutide at all. Australia's Therapeutic Goods Administration tested an unmarked vial sold as retatrutide after a person was hospitalized with uncontrollable vomiting and a torn esophagus, and found undeclared semaglutide at about 8 times the level in approved semaglutide products. The primary source is the TGA's safety advisory.
Key takeaways
- Australia's Therapeutic Goods Administration (TGA) published a safety advisory on September 14, 2026 after a person was hospitalized with uncontrollable vomiting and a torn esophagus.
- The TGA's lab found no retatrutide in the unmarked vial, only undeclared semaglutide at about 8 times the level in approved semaglutide products.
- The TGA says retatrutide isn't approved by it or any comparable regulator, and any product outside a clinical trial could be counterfeit.
- In this case a label saying retatrutide told you nothing about what was in the vial.
This page records the advisory and the Australian alerts around it. The running log of regulator actions in every country is on the safety alerts page.
What the TGA reported on September 14
The TGA received a report of a serious adverse event: a consumer had uncontrollable vomiting and a tear in the esophagus, the tube from the throat to the stomach, and needed hospital treatment after using a product sold as retatrutide. The TGA's laboratory then tested the unmarked vial. It found no retatrutide. It found semaglutide, which wasn't declared, at about 8 times the level in approved semaglutide products on the Australian Register of Therapeutic Goods (ARTG).
The advisory also restates the legal position. Retatrutide isn't approved by the TGA or any comparable international regulator, and any product outside a clinical trial could be counterfeit.
The TGA retatrutide alert alongside Australia's other warnings
It wasn't the first Australian warning in 2026.
| Date | Who | What it said |
|---|---|---|
| Jun 19, 2026 | Victoria's Chief Health Officer | 6 cases of acute liver injury since January 2026 in people using an unapproved product labeled Retatrutide, possibly from a contaminant; all products labeled Retatrutide at risk |
| Jun 19, 2026 | TGA and Australia's Chief Medical Officer | Serious harms reported with unapproved peptides, including liver damage and severe allergic reactions; retatrutide named among unevaluated products |
| Sep 14, 2026 | TGA | Vial sold as retatrutide held semaglutide and no retatrutide |
Victoria's alert was still active on October 31, 2026, still at 6 cases. The symptoms it lists are tiredness, yellowing skin or eyes (jaundice), belly pain, dark urine and unusual bruising.
What the test means
A label is a claim, and this one was wrong twice: wrong drug, and far too much of it. Lilly's October 2026 FAQ warns that illicit products may hold unknown ingredients, contaminants, too much or too little of the active ingredient, or the wrong ingredient entirely. This vial was the last of those.
Our read: whatever a listing of retatrutide for sale says on its label or certificate, only a batch-specific lab test tells you what's in the vial, and even that only covers the batch tested. The testing page explains how to read one.
When to get help
Get medical care straight away for vomiting that won't stop, being unable to keep fluids down, vomiting blood, or chest pain after vomiting. See a doctor promptly for yellow skin or eyes, dark urine or belly pain, the liver signs on Victoria's list. In Victoria, the Poisons Information Centre is on 13 11 26.
What's still unknown
The TGA didn't name the seller. A letter in Drug and Alcohol Review looked at the makeup and labeling of products sold as retatrutide in Australia, but we couldn't get its text, so none of its findings are here. Whether owning or importing a vial is legal where you live is on the is retatrutide legal page, and is retatrutide safe separates the trial safety data from these products.
Frequently asked questions
What did the TGA find in the retatrutide vial?
No retatrutide at all. The vial held undeclared semaglutide, the drug in Ozempic and Wegovy, at about 8 times the level found in approved semaglutide products on the Australian Register of Therapeutic Goods.
What happened to the person who used it?
The TGA says the consumer had uncontrollable vomiting and a torn esophagus and needed hospital treatment after using the product.
Is retatrutide legal in Australia?
The TGA says retatrutide isn't approved by the TGA or any comparable international regulator. Its advisory lists penalties of up to $1.82 million per breach for a person and $18.2 million for a corporation, and criminal penalties of up to 7 years' imprisonment.
What should I do if I've used a vial like this?
Stop using it and get medical help if you're unwell, especially with vomiting that won't stop, yellow skin or eyes, dark urine or belly pain. In Victoria, the Poisons Information Centre is on 13 11 26.
Sources
- TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration (Australia), 2026. tga.gov.au
- Toxicity linked to unapproved peptide Retatrutide. Department of Health, Victoria (Australia), 2026. health.vic.gov.au
- Concerns regarding public health risks associated with unapproved peptide products. Therapeutic Goods Administration (Australia), 2026. tga.gov.au
- What to know about retatrutide. Eli Lilly and Company, 2026. lilly.com
Dr. Juan Pablo Frías, MD
Physician-Scientist & Clinical Trialist • Endocrinology, Diabetes & Metabolism
Dr. Frías earned his M.D. from Vanderbilt University School of Medicine and completed his endocrinology fellowship at UC San Diego. A principal investigator on landmark incretin trials (including retatrutide, tirzepatide and semaglutide), he reviews all guides on Retatrutide360 for clinical accuracy, dosing safety and evidence fidelity.
Related guides & clinical tools
Continue reading our evidence-backed guides and use our syringe calculation tools.
Retatrutide Safety and Regulatory Alerts
Every retatrutide FDA warning letter, regulator alert, seizure, lawsuit and lab test we could check, newest first, each linked to its source and date-stamped.
Retatrutide Testing
Retatrutide testing explained: what a COA's identity, purity and mg results prove, what they miss, how to check a Janoshik report, and what fakes held.
Is Retatrutide Legal? US, UK, Canada and Australia
Is retatrutide legal? Not to sell anywhere, as of October 2026. See what the FDA, MHRA, Health Canada and TGA say about buying, importing and owning it.
Is Retatrutide Safe? Risks, Warnings and Blood Work to Monitor
Is retatrutide safe? What 6 Phase 3 trials show on side effects, quit rates and the heart, how it compares with Ozempic, and why online vials are another risk.
Retatrutide News and Updates (October 2026)
Retatrutide news, October 2026: the first head-to-head win over Ozempic, the FDA's drug-not-biologic decision, new NEJM papers and the crackdown on sellers.
Turn any dose into syringe units
Vial, water and dose in, exact syringe units out. Calculates reconstitution volumes and needle tick marks for 5 mg to 60 mg vials with zero guesswork.